Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression

Transplantation

Volumn 67, Issue 6, 1999, Pages 846-854

  Thomas, Francis T ^a   Ricordi, Camillo ^b   Contreras, Juan L ^a   Hubbard, William J ^a   Jiang, Xiao Ling ^a   Eckhoff, Devin E ^a   Cartner, Samuel ^c   Bilbao, Guadalupe ^c   Neville Jr , David M ^d   Thomas, Judith M ^a,c  

^a UAB Department of Surgery   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI CD3 IMMUNOTOXIN; CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; UNCLASSIFIED DRUG; INSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MONKEY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; XENOGRAFT; ANIMAL; CERCOPITHECUS; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MACACA; MALE; SECRETION;

ANIMALS; CERCOPITHECUS AETHIOPS; DIABETES MELLITUS, TYPE 1; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MACACA FASCICULARIS; MACACA MULATTA; MALE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033608550     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903270-00011     Document Type: Article

References (36)

1. Weir GC, Bonner-Weir S. Scientific and political impediments to successful islet transplantation. Diabetes 1997; 46: 1247.
2. Lasker RD. The diabetes control and complications trial: implications for policy and practice. N Engl J Med 1993; 329: 1035.
3. Stratta RJ, Weide LG, Sindhi R, et al. Solitary pancreas transplantation: experience with 62 consecutive cases. Diabetes Care 1997; 20: 362.
4. Thomas FT. Isolated pancreatic islet grafting. In: Cooper DKC, Kemp E, Reemtsma K, White DJG, eds. Xenotransplantation. New York: Springer-Verlag, 1997: 545.
5. Sutherland DE. Pancreas transplantation as a treatment for diabetes: indications and outcome. Curr Ther Endocrinol Metab 1997; 6: 496.
6. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72: 175.
7. Reckard CR, Barker CF. Transplantation of isolated pancreatic islets across strong and weak histocompatibility barriers. Transplant Proc 1973; 5: 761.
8. Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51: 76.
9. Hering BJ, Browatzki CC, Schultz AO, Bretzel RG, Federlin K. Islet Transplant Registry report on adult and fetal islet allografts. Transplant Proc 1994; 26: 565.
10. Thomas FT, Thomas JM. Immunomodulation of islet transplants: future prospects. In: Lanza R, Langer W, Chick W, eds. Principles of tissue engineering. Austin, TX: Landes Company, 1997: 404
11. Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 335: 860.
12. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997; 46: 1907.
13. Thomas FT, Pittman K, Berzina P, et al. Pancreas islet xenografts but not allografts are resistant to autoimmune disease recurrence following islet transplantation. Transplant Proc 1997; 29: 760.
14. Kenyon NS, Alejandro R, Mintz DH, Ricordi C. Islet cell transplantation: beyond the paradigms. Diabetes Metab Rev 1996; 12: 361.
15. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. Normalization of diabetes in spontaneously diabetic cynomolgus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J Clin Invest 1996; 98: 1417.
16. Scharp DW, Swanson CJ, Olack BJ, et al. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 1994; 43: 1167.
17. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187.
18. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
19. Thomas JM, Neville DM, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64: 124.
20. Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998; 65: 1159.
21. Neville DM Jr, Scharff J, Hu HZ, et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J Immunother Emphasis Tumor Immunol 1996; 19: 85.
22. Hu H, Stavrou S, Cairns BB, et al. Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys. Cell Immunol 1997; 177: 26.
23. + T cells. J Exp Med 1989; 170: 991.
24. Lakey JR, Warnock GL, Brierton M, et al. Development of an automated computer-controlled islet isolation system. Transplant Proc 1997; 29: 1956.
25. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286.
26. Meyer S, Kohler NG, Joly A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 1997; 413(2): 354.
27. Neville DM Jr, Scharff J, Srinivasachar K. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992; 89: 2585.
28. Cosimi AB, Delmonico FL, Wright K, et al. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery 1990; 108: 406.
29. Jonker M, Goldstein G, Balner H. Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model. Transplantation 1983; 35: 521.
30. Thomas FT, Carver FM, Foil MB, et al. Long term incompatible kidney survival in outbred primates without chronic immunosuppression. Ann Surg 1983; 198; 370.
31. Martin LN, Gormus BJ, Bozelka BE. Functional analysis of monkey lymphocyte subsets defined by OKT4 and OKT8 monoclonal antibodies. Cell Immunol 1983; 77: 38.
32. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (noninsulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 1986; 29: 713.
33. Van Beusechem VW, Valerio D. Gene transfer into hematopoietic stem cells of nonhuman primates. Hum Gene Ther 1996; 7: 1649.
34. Clarkson TB, Koritnik DR, Weingand KW, Miller LC. Nonhuman primate models of atherosclerosis: potential for the study of diabetes mellitus and hyperinsulinemia. Metab Clin Exp 1985; 34: 51.
35. Howard CF. Atherosclerosis and insulin in primates with diabetes mellitus. Metab Clin Exp 1985; 34: 60.
36. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short-and long-term kidney graft survival [see comments]. Transplantation 1995; 60: 1384.